Needham Lowers MapLight Therapeutics Target to $43

Maplight Therapeutics MPLT continues to see price-target changes from Needham & Company LLC, with Needham lowering its target from $45 to $43 while maintaining a Buy rating, signaling potential upside that varies across reports. Other analysts have displayed mixed views, with firms issuing benchmarks from strong buy to hold, and MarketBeat aggregating a Moderate Buy consensus with an average target around $29.50. MPLT’s latest quarterly results showed a loss of $1.32 per share, beating consensus estimates by $0.08, and the outlook calls for a full-year loss near $5.12 per share. The constellation of updates suggests cautious optimism among bulls, but a broad range of price targets and ratings underscores ongoing volatility in MPLT’s coverage. Investors are watching how these divergent estimates translate into actual stock performance as Needham’s target remains notably higher than peers’ lower targets. Overall, the coverage indicates continuing scrutiny of MPLT’s earnings trajectory and valuation as analysts reassess growth prospects.